

May 17, 2021

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Intimation of suit filed by Panacea Biotec Limited (“Company”) against Sanofi Healthcare India Private Limited

Dear Sir/Madam,

With reference to the captioned subject, we would like to inform you that the Company has instituted a suit before the Hon’ble Delhi High Court seeking to restrain Sanofi Healthcare India Private Limited from marketing a fully liquid hexavalent vaccine that would infringe Company’s patent for its fully liquid Whole Cell Pertussis based fully liquid Hexavalent Vaccine, EasySix™.

Panacea Biotec’s EasySix™ is a first of its kind Whole Cell Pertussis based fully liquid Hexavalent Vaccine which comes in a pre-filled syringe and is used to vaccinate against, Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza type b and Inactivated Polio (DTwP-HepB-Hib-IPV). EasySix™ has been in the market since 2017.

A brief note in respect of the above mentioned matter is enclosed herewith for your kind information and record please.

Kindly acknowledge the receipt.

Thanking you,
Yours Sincerely

For Panacea Biotec Ltd.



Vinod Goel
Group CFO and Head Legal
& Company Secretary

Encl.: as above

PANACEA BIOTEC LIMITED vs SANOFI HEALTHCARE INDIA PRIVATE LIMITED

Panacea Biotec Limited instituted a suit before the Delhi High Court seeking to restrain Sanofi Healthcare India Pvt. Ltd. from marketing a fully liquid hexavalent vaccine that would infringe Panacea's patent for its fully liquid Whole Cell Pertussis based fully liquid Hexavalent Vaccine, EasySix™. Sanofi has been contesting the Panacea patent before the Indian Patent Office since 2017, where the dispute has spilled before the Bombay and Delhi High Courts in 2018 and 2019, respectively.

Panacea Biotec's EasySix™ is a first of its kind Whole Cell Pertussis based fully liquid Hexavalent Vaccine which comes in a pre-filled syringe and is used to vaccinate against, Diphtheria, Tetanus, Whooping Cough, Hepatitis B, *Haemophilus influenza type b* and Inactivated Polio (DTwP-HepB-Hib-IPV). EasySix™ has been in the market since 2017 and, as Panacea Biotec expects, will be made available in government vaccination/immunization programmes, both domestically and internationally.

The suit filed against Sanofi comes at the heels of the Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent vaccine (DTwP-HepB-Hib-IPV) by the Drugs Controller General (India). On 11.05.2021, when the suit was listed before the Hon'ble Delhi High Court, after elaborate submissions from both parties, Sanofi undertook that it would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351, at this stage.

The battle for Whole Cell Pertussis based vaccines has several aspects and considerations in the global market. Currently, there are two types of pertussis vaccines licensed for use: whole cell pertussis (wP) and acellular pertussis (aP). Immunization with wP vaccines has been deemed as comparably effective and relatively inexpensive. Although aP vaccines have gradually supplanted the use of wP vaccines in industrialized countries, the significantly higher development and production costs of aP vaccines result in prices that are much higher than that of a dose of wP vaccine. Since the relative protective efficacy of the best wP and aP vaccines appear comparable and the adverse events of both vaccines are relatively minor, wP vaccines remain the vaccine of choice in many developing countries.

Before the Court, Sanofi will now tender its response to Panacea Biotec's claims and the detailed arguments in the suit shall follow.

Senior Advocate, Mr. C.S. Vaidyanathan argued for Panacea Biotec, instructed by S. Majumdar & Co. while, Senior Advocate, Mr. Sudhanshu Batra, appeared for Sanofi, instructed by M/s Anand & Anand.



Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Regd. Office : Ambala Chandigarh Higway, Lalru – 140501, Punjab

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com